WORLD NEWS
Two-year GLP-1 discontinuation linked to 22% higher relative cardiovascular risk in type 2 diabetes
The study included 132,551 new GLP-1 users with type 2 diabetes, reassigned treatment status every six months and compared three-year outcomes.
Risk ratios were 1.04 after 0.5 years off, 1.14 after one year and 1.22 after two; veteran-heavy data and residual confounding limit personal predictions.
What does 22% compare?
It is relative to a continued-use strategy and combines myocardial infarction, stroke and all-cause death. It is not a 22-percentage-point rise in an individual’s absolute probability.
Study design
US Veterans Affairs data from 2017–2023 included 132,551 new GLP-1 users and 201,136 sulfonylurea users. Prescriptions emulated a target trial; people were not randomly assigned.
Why caution?
Cost, side effects or worsening illness can cause discontinuation and also relate to risk. Adjustment cannot remove every such residual difference.
What patients should do
Discuss side effects, cost, alternatives, dose and monitoring with the prescriber. This study does not establish benefits of self-directed continuation, restarting or tapering.
Primary source and independent checks
Nature Reviews Endocrinology 독립 검토
Read in other languages
한국어 · English · Español · 日本語 · Tiếng Việt